Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 12% - Still a Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s stock price traded up 12% during trading on Wednesday . The company traded as high as $10.98 and last traded at $11.39. 453,155 shares traded hands during trading, a decline of 77% from the average session volume of 1,974,308 shares. The stock had previously closed at $10.17.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Alliance Global Partners assumed coverage on Capricor Therapeutics in a research note on Monday, June 30th. They set a "buy" rating and a $20.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, June 24th. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. B. Riley assumed coverage on Capricor Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $21.00 price target on the stock. Finally, Jones Trading decreased their price target on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research note on Wednesday, June 25th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and an average price target of $32.22.

Capricor Therapeutics Stock Up 12.4%

The firm has a fifty day simple moving average of $10.47 and a 200-day simple moving average of $12.18. The company has a market cap of $522.36 million, a PE ratio of -8.09 and a beta of 0.82.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same period in the previous year, the business posted ($0.31) EPS. Equities research analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. boosted its stake in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares during the period. Krilogy Financial LLC boosted its stake in shares of Capricor Therapeutics by 9.6% during the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock worth $216,000 after buying an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Capricor Therapeutics by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company's stock worth $1,079,000 after buying an additional 2,314 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after buying an additional 2,361 shares during the period. Finally, Invesco Ltd. lifted its position in Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.